News & AnalysisMedicine

Frightening Risk of Marfan Syndrome, and Potential Treatment, Elucidated

See allHide authors and affiliations

Science  15 Apr 2011:
Vol. 332, Issue 6027, pp. 297
DOI: 10.1126/science.332.6027.297

eLetters is an online forum for ongoing peer review. Submission of eLetters are open to all. eLetters are not edited, proofread, or indexed.  Please read our Terms of Service before submitting your own eLetter.

Compose eLetter

Plain text

  • Plain text
    No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Enter the characters shown in the image.

Vertical Tabs

  • The Tall Risk of Marfan Syndrome

    The 15 April 2011 issue of Science reports a potentially groundbreaking new use of the drug losartan in the treatment of Marfan syndrome (1, 2). The blood pressure reducer shows great potential to slow or even stop the progression of life-threatening aortic aneurysms associated with the disorder. In the News & Analysis story highlighting the excitement surrounding these findings ("Frightening risk of Marfan syndrom...

    Show More
    Competing Interests: None declared.